https://www.selleckchem.com/pr....oducts/epertinib-hyd
05), with a 29.5% reduction in opioid consumption for 24 hours and fewer demands for patient-controlled analgesia. In the rescued subgroup, VVZ-149 further reduced pain intensity (P .05) with 32.6% less opioid consumption for 24 hours compared to placebo patients. VVZ-149 demonstrated effective analgesia with reduced postoperative pain and opioid requirements. Consistent with the results from the previous Phase 2 study, patients with early rescue requirement had greater benefit from VVZ-149, supporting the hypothesi
Like
Comment
Share
